{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T03:44:37Z","timestamp":1766720677007,"version":"3.46.0"},"reference-count":25,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome caused by uncontrolled immune activation and hemophagocytosis. In adults, Epstein-Barr virus (EBV) infection is a known trigger. This report describes a novel approach to treating EBV-induced HLH in a 29-year-old female, avoiding the potential toxicities of chemotherapy-based regimens, such as infertility.<\/jats:p>\n                  <jats:p>The patient presented febrile, tachycardic, and hypotensive following a week of high fever, bilious emesis, and diarrhea. Laboratory results showed elevated AST and ALT, hyperbilirubinemia, leukopenia, thrombocytopenia, and hyperferritinemia. Imaging revealed splenomegaly, and a positive mononucleosis rapid test confirmed EBV infection. Based on her clinical presentation, laboratory findings, and a bone marrow biopsy showing phagocytic histiocytes, she was diagnosed with EBV-induced HLH, fulfilling 7 of the 8 diagnostic criteria (5 required).<\/jats:p>\n                  <jats:p>The patient was started on the DAIR regimen two days after transfer. DAIR combines dexamethasone for its potent anti-inflammatory properties (used in HLH-94\/HLH-2004), anakinra to control the cytokine storm, IVIG for passive immune support and antiviral action, and rituximab to target EBV-infected B cells.<\/jats:p>\n                  <jats:p>The patient responded well to treatment. EBV became undetectable within three weeks, and by seven weeks, blood counts, liver function, ferritin, triglycerides, and fibrinogen levels had normalized. Ten weeks after symptom onset, she returned to work and is now pregnant, with no signs of relapse.<\/jats:p>\n                  <jats:p>This case demonstrates the effectiveness of DAIR as a chemotherapy-free alternative for EBV-induced HLH, offering a targeted approach to the syndrome\u2019s complex pathogenesis while achieving sustained remission.<\/jats:p>","DOI":"10.46989\/001c.143659","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:34:57Z","timestamp":1759941297000},"source":"Crossref","is-referenced-by-count":1,"title":["DAIR to Be Different: Successful Use of DAIR Regimen, a Novel Treatment Combination for EBV-induced HLH"],"prefix":"10.46989","volume":"7","author":[{"given":"Adam","family":"Bouhadana","sequence":"first","affiliation":[{"name":"New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[{"name":"New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, United States"},{"name":"Hematology and Oncology, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26435","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"L. Fardet","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ando.2023.03.013","article-title":"Chemotherapy and female fertility","volume":"84","author":"I. Sellami","year":"2023","journal-title":"Ann Endocrinol"},{"key":"ref3","article-title":"label"},{"journal-title":"Journal of Clinical Oncology","article-title":"Predicting etoposide toxicity: relationship to organ function and protein binding","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.257"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2018.05.009","article-title":"The role of immunotherapy in in vitro fertilization: a guideline","volume":"110","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2018","journal-title":"Fertil Steril"},{"issue":"8","key":"ref6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.medcli.2016.05.020","article-title":"[Treatment with immunosuppressive and biologic drugs of pregnant women with systemic rheumatic or autoimmune disease]","volume":"147","author":"J. Alijotas-Reig","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jri.2019.06.001","article-title":"Treatment with intravenous immunoglobulin in patients with recurrent pregnancy loss: An update","volume":"133","author":"O. B. Christiansen","year":"2019","journal-title":"J Reprod Immunol"},{"article-title":"Anakinra Therapy for Hemophagocytic Lymphohistiocytosis: CADTH Health Technology Review","year":"2022","author":"S. Ndegwa","key":"ref8"},{"issue":"19","key":"ref9","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.3390\/jcm11195799","article-title":"Anakinra for the Treatment of Hemophagocytic Lymphohistiocytosis: 21 Cases","volume":"11","author":"C. Baverez","year":"2022","journal-title":"J Clin Med"},{"article-title":"Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis - Lee - 2023 - European Journal of Haematology - Wiley Online Library","key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14030"},{"issue":"2","key":"ref11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"J. I. Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"ref12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12098-014-1461-0","article-title":"Profile of Hemophagocytic Lymphohistiocytosis; Efficacy of Intravenous Immunoglobulin Therapy","volume":"81","author":"S. Rajajee","year":"2014","journal-title":"Indian J Pediatr"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","article-title":"Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens","volume":"162","author":"D. Chellapandian","year":"2013","journal-title":"Br J Haematol"},{"key":"ref14","series-title":"StatPearls","article-title":"Dexamethasone","author":"D. B. Johnson","year":"2025"},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00063030-200216040-00005","article-title":"Anakinra","volume":"16","author":"R. S. Cvetkovic","year":"2002","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse Effects of Immunoglobulin Therapy","volume":"9","author":"Y. Guo","year":"2018","journal-title":"Front Immunol"},{"key":"ref17","series-title":"StatPearls","article-title":"Rituximab","author":"N. Hanif","year":"2025"},{"key":"ref18","series-title":"StatPearls","article-title":"Lymphohistiocytosis","author":"S. Konkol","year":"2024"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3389\/fimmu.2017.01902","article-title":"Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis","volume":"8","author":"R. A. Marsh","year":"2017","journal-title":"Front Immunol"},{"key":"ref20","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation | Blood | American Society of Hematology"},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","article-title":"Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis","volume":"89","author":"S. A. Parikh","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"ref22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000514920","article-title":"The Efficacy of Etoposide-Based Therapy in Adult Secondary Hemophagocytic Lymphohistiocytosis","volume":"144","author":"L. Naymagon","year":"2021","journal-title":"Acta Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.clinpr.2020.100060","article-title":"Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report","volume":"9","author":"N. McCann","year":"2021","journal-title":"Clin Infect Pract"},{"issue":"9","key":"ref24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis","volume":"34","author":"P. Wohlfarth","year":"2019","journal-title":"J Intensive Care Med"},{"author":"HScore","key":"ref25","article-title":"H\u00f4pital Saint-Antoine AP-HP"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/143659-dair-to-be-different-successful-use-of-dair-regimen-a-novel-treatment-combination-for-ebv-induced-hlh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:33:31Z","timestamp":1764700411000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/143659-dair-to-be-different-successful-use-of-dair-regimen-a-novel-treatment-combination-for-ebv-induced-hlh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.143659","relation":{},"ISSN":["2590-0048"],"issn-type":[{"type":"electronic","value":"2590-0048"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}